吡柔比星、多柔比星治疗非霍奇金淋巴瘤的疗效对比观察

目的：了解吡柔比星与多柔比星用于非霍奇金淋巴瘤（NHL）化疗的临床疗效。方法：选择本科2007年7月～2010年6月收治并确诊的NHL患者85例,将其随机分为吡柔比星组48例接受以吡柔比星为主的化疗方案,多柔比星组37例接受以多柔比星为主的化疗方案,对比分析两组的疗效与不良反应。结果：吡柔比星组化疗的有效率为83.3%,多柔比星组为67.6%,两组比较,差异有统计学意义（P〈0.05）。多柔比星组发生较多的心脏毒性反应,吡柔比星组则未发生心脏毒性反应,吡柔比星对胃肠道的不良反应较低。结论：与多柔比星为主的方案相比,以吡柔比星为主的化疗方案NHL的疗效更佳,不良反应较小,值得临床推广应用。

Therapeutic effects observation of pirarubicin and doxorubicin on the nonhodgkin lymphoma (NHL) chemotherapy

Objective：To study the therapeutic effects of pirarubicin and doxorubicin for non-hodgkin lymphoma（NHL） chemotherapy.Methods：85 NHL patients were slected from July 2007 to June 2010 and were divided into pirarubicin group 48 cases and doxorubicin group 37 cases,they were cured by pirarubicin-dominant or doxorubicin-dominant chemotherapy regimen,the therapeutic effects and ADRs of the two groups were compared and analyzed.Results：The effective rate of pirarubicin group was 83.3%,the doxorubicin group was 67.6%,the difference was significant（P0.05）.Doxorubicin group showed more cardiac toxicity and gastrointestinal tract ADR;Pirarubicin group showed less gastrointesti nal tract ADRs and no cardiac toxicity.Conclusion：Compares to doxorubicin-dominant regimen,pirarubicin-dominant chemotherapy regimen showes better therapeutic effect,less ADR and clinical potential.